Document is current
Any future updates will be listed below
-
Authors
Giannotti, Giuseppe http://orcid.org/0000-0003-0629-4882
Mottarlini, Francesca
Heinsbroek, Jasper A. http://orcid.org/0000-0003-4641-6899
Mandel, Mitchel R.
James, Morgan H. http://orcid.org/0000-0001-9298-8607
Peters, Jamie http://orcid.org/0000-0002-7573-6384
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (DA045836, DA044524, DA038235, DA048974, DA045765)
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse
U.S. Department of Health & Human Services | NIH | NIH Office of the Director (OD026407)
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse
- License Information
-
More Information
Article History
Received: 8 February 2022
Revised: 6 September 2022
Accepted: 8 September 2022
First Online: 4 October 2022
Competing interests
: JP is a consultant for Delix Therapeutics, Inc.
